The Competition Commission of South Africa, is investigating the price of US pharmaceutical manufacturer Gilead Science’s coronavirus treatment remdesivir and prices charged by generic firms to which it granted manufacturing license after a complaint by activists and researchers.
Commission spokesperson Makunga Siyabulela said on Monday, August 31, that the organization received a request from non-profit organisation the Health Justice Initiative (HJI) and Wits research unit Ezintsha to examine the price of remdesivir. “It is … currently under investigation and remedies are likely to be behavioural and/or an administrative penalty, if there is a finding of a contravention,” he said.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI